On this World Blood Donor Day, let’s explore some Israeli tech that is making a difference to one of our most vital components: our blood

Hematological awareness is important as body vitality is exclusively dependent on blood flow. Blood is our natural producer of oxygen and carbon dioxide, and it is also a key mechanism for medical identification. For decades, doctors have prioritized blood analytics and testing as these results present in-depth information regarding diagnostics, treatment methods, and one’s overall physical state. Blood is as much the cure as it is the cause– blood donations are organized worldwide to act as a remedy for the shortage of blood and blood products that can single-handedly save hundreds of lives. Here in Israel, MedTech’s innovative efforts have always been advanced, yet amidst the effects of COVID-19 and how it continues to modify all spheres of society, Israeli MedTech innovations are at an all-time high. With the focus strictly on blood analytics, Israel’s start-up environment has pushed forth incentives and actions that have seemingly revolutionized how blood can be analyzed, detected, and measured. Here are some Israeli startups that play a role in hematology solutions.

PixCell

Blood diagnostic information, in most cases, does not do enough to create an effective impact on immediate health solutions and products. The devices and technologies that have been used thus far do not provide doctors and patients with substantial information when it matters most. Moreover, real-time blood testing is not accessible to everyone which presents numerous implications when patients are in emergencies. These obstacles have disrupted medical efforts for decades as there is a pressing need for in-depth, easily accessible blood diagnostic tools. In an accidental discovery made by a team of researchers at the Technion (Israel Institute of Technology), Viscoelastic Focusing (VEF) has been recognized as the saving grace toward efficient cell analytics. The Israeli startup PixCell has created the HemoScreen that uses advanced technology making use of VEF potential. This product uses a disposable cartridge with specific reagents to elicit a Complete Blood Count test. HemoScreen does not require maintenance or calibration and is versatile to fit the precise needs of its user.

PixCell was founded in 2008 with a keen focus on simplifying and regularizing real-time blood testing worldwide. Their research and entrepreneurial staff have surpassed company expectations with the discovery of Viscoelastic Focusing (VEF), paving a way for pivotal advancements in hematological efforts. Their team consists of Avishay Bransky (CEO, Co-Founder), Prof. Max Herzberg (Co-Founder), Armin Schon (CCO), Hanan Ben-Asher (COO, BD Manager), Mark Erez (CFO), Yaara Ben-Yosef (Director of RA and Clinical Affairs), and Eitan Hod (Director of QA and RA). PixCell has raised over $7 million in grant funding from the European Commission, the International Health-Tech Pilot Program, and the Israel Innovation Authority. In 2021 PixCell was acquired by Soulbrain Holdings.

RedC Biotech

The global supply of red blood cells has seeped far under worldwide medical demands. This shortage has served as a detriment to medical interventions such as trauma, childbirth, operations, chronic illness, cancer, and the list goes on. Red blood cells are the oxygen-carrying capacity of the body which is why 120 million blood units are donated each year, yet there is still a concerning decrease in these donations. Blood drives and donation sites, although they function as a temporary solution, are still not enough to compensate for the urgency in transfusion methods, productions, and resources. The Israeli startup RedC Biotech has initiated a “one blood type fits all” method with RedC Universal Red Blood Cell Transfusions. This product is suitable for almost every patient and provides a uniform potency. It is pathogen-free and donor free and also eliminates undesirable blood components as well as additional hospital testing.

Credit: RedC Biotech

RedC was founded in Haifa in 2015 by Dr. Ari Gargir. Over the past couple of years, the company has received $1.4 million in pre-seed and seed funding from PipelBiz. Their revolutionary technology addresses issues associated with industrial red blood cell production, and cost reductions. From the lab to global production, Red C Biotech is eager to scale the count of red blood cells to save lives worldwide. RedC has a small employee base but is growing in accordance with its production timeline.

Improdia

Current diagnostic tests cannot distinguish between acute and chronic inflammation, as well as monitoring immune functions that are pivotal for personalized treatment methods. With Improdia’s array of Unique BioMarkers, the innovative diagnostic company has developed a simple way to supervise inflammation levels for patients suffering from autoimmune and cancer diseases. ImproDdia’s technology department has made substantial discoveries enabling pharma companies a kickstart in their drug development processes as well as suggesting personalized treatment methods. Improdia’s Diagnostic Kit includes three easy-to-use, unique biomarkers with three distinct functions: the IMPC (for chronic inflammation), IMPI (for immunotherapy), and IMPD (for diabetes complications. IMPC evaluates the immune status and inflammatory pain levels of those with niche medical implications. It aids physicians in selecting the type and timing of specific treatments as well as monitoring the efficacy of such treatments. IMPI is a prognostic test for the efficiency of immunotherapy. It monitors the immune status of cancer patients before immunotherapy or chemotherapy. IMPD is a prognostic test for diabetes complications as it predicts the occurrence of these complications before they are medically obvious.

Improdia’s team consists of Miriam Lerner (Founder, Co-CEO, CTO), Gil Pogozelich (Chairman), Dr. Roy Eldor (Medical Director), Prof. Michal Baniyash (Inventor), and Prof. Ido Wolf (Member of the Scientific Advisory Board). The company has been based in Herzliya since 2012 and continues to aid doctors and patients in the diagnostic and management endeavours of those with chronic immune-mediated diseases.

Sight Diagnostics

Sight’s technology represents breakthrough innovations in diagnostic methodology. Their latest blood analyzer, Sight OLO, performs a Complete Blood Count, the most ordered blood test, in minutes. It’s compact and designed to be used in a variety of settings. OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms, and the results are available within minutes.

Sight OLO provides 5-part differential complete blood count (CBC) results with 19 parameters and sophisticated flagging capabilities, for on-site testing. It is the first CBC analyzer that is FDA 510(k) cleared for blood taken directly from either a finger prick or a venous sample. Sight OLO has been validated for use in patients 3 months and above, in a variety of CLIA-certified (Clinical Laboratory Improvement Amendments) moderately complex clinical settings such as hospitals, emergency departments, oncology clinics, pediatric practices, and urgent care locations. The sample preparation process can be completed in under one minute, with the full results ready in minutes on a touchscreen interface, printout, email, or via LIS (Latent Semantic Indexing)/middleware. Sight OLO comes factory calibrated for a quick setup with internal Failsafe systems and requires no maintenance. Its minimal training and step-by-step on-screen guidance are designed to be used by operators with any level of experience. OLO also has an Operator Management feature that allows for complete control over who can access the device, including traceability of operator activities.

Sight OLO was founded in 2011 by Yossi Pollack (CEO) and Daniel Levner (Chairman of the Scientific Advisory Board). The company is based in Tel Aviv, London, and Brooklyn with 300 employees. With investments from Koch Disruptive Technologies, OurCrowd, and Longliv, Sight Diagnostics has raised over $120 million to date. Sight has gained worldwide traction with partners eager to use and expand the company’s advanced technology. Among them are Boston Children’s Hospital, Oxford University Hospitals NHS Foundation Trust, and Nicklaus Children’s Hospital in Miami.

EFA

Handheld blood test diagnostic tools are not affordable for the average patient and consumer. Most of these tools require laboratory conditions and specific preparations which fail to account for real-time informed decisions an individual may have to make. Israeli startup EFA developed RevDx™, a revolutionary, European Commission-approved, mobile, and fully automated diagnostic system to be used for different care, including primary care physicians, home care, emergency care, and remote care. RevDx™ is easy-to-use; from a finger prick, you get results within minutes. The application provides a Complete Blood Count test, the most requested hematology test worldwide which provides indications for broad clinical conditions such as infections, disease, fever, immune system, and anemia.

Founded in 2016 by Yoel Ezra (CEO), an engineer and a physicist who served in a technological-operation unit in the IDF for over 23 years, EFA is acting to develop the RevDx solution as a platform that will enable the creation of more diagnostic applications over time. Among the company’s investors are Maccabi Healthcare Services, eHealth Ventures, Merchavia, and Medison. The company currently employs 12 people.

OrSense

Diverse clinical settings have not found easy nor accurate methods to measure blood parameters as current testing devices and tools are not appropriately equipped for such conditions. The key to medical testing is to establish a comfortable environment for any and all patients; with invasive monitoring, though, this element is rather ignored. Israeli startup OrSense works to transform patient health through non-invasive monitoring as they develop and commercialize innovative monitoring technologies focused primarily on donor and patient comfort. Using their revolutionary SpectOLight ™ Occlusion Spectroscopy Technology, OrSense has developed the NBM 200 Device that detects blood hemoglobin (Hb), oxygen saturation levels and pulse rate (PR) values. Patients place their fingers on a ring-sensor probe where the portable desktop attached to the monitor device calculates and displays the figured measurements. To make matters even easier and more efficient, OrSense has developed a software application attached to the device that allows for Tablet or Smartphone use.

Since 1996 OrSense has been working worldwide to overcome key obstacles that do not account for comfortable, accessible, and efficient blood parameter testing. For over 20 years, OrSense has made substantial adjustments toward non-invasive monitoring technologies: the intellectual property portfolio at OrSense consists of 51 granted patents and over 20 additional applications. So far, OrSense has raised over $44.4 million in seed and grant funding from Israel HealthCare Ventures, Star Ventures, Saints Capital, The Lewis Trust Group, and Shimon Eckhouse. Their team consists of Yoav Resiman (Founder and CEO), Aharon Weinstein (VP of Research). Asher Zysman (CFO), and Chip Neff (President). OrSense is located both in Tel Aviv, and Raleigh, North Carolina, USA.

PatenSee

Patients who suffer from renal failure are required to be connected to a hemodialysis machine for a few hours, 2-3 times a week, via a fistula on the patient’s arm. The fistula is the point of connection between the hemodialysis machine and the patient for the treatment. One of the most dreaded complications for hemodialysis patients is fistula loss due to stenosis (blood clogging of the fistula) resulting in an inability to perform routine dialysis – a major risk to patient life. PatenSee is a medical device company (currently in the clinical stage) that has developed a contactless, machine vision-based, surveillance system for the early detection of vascular stenosis and/or a clogged fistula. The technology is designed to provide a very simple way to improve the quality of patient care and to support the nursing staff in the hemodialysis center without adding any burden on the patient or the clinic. The system can also be adapted to home use adding a critical diagnostic feature to home dialysis.

PatenSee was founded in 2019 as a portfolio company of MEDX Xelerator, a MedTech incubator working under a license from the Israel Innovation Authority. Hagay Drori and Oz Seadia founded PatenSee based on an unmet need presented to the MEDX Xelerator by a major strategic player in the dialysis field. Dr. Gal Goshen, PatenSee’s CEO, led it from its early concept through its first-in-human 60-patient clinical study, conducted less than two years after the company’s founding. PatenSee is currently raising a Series A round and is preparing for a multi-center, international, clinical trial of its second-generation imaging system.

ILAN founder aims to create warm ties with Israel among the growing Spanish-speaking population.

The Israel Latin America Network (ILAN), established last year by Jewish Mexican-Syrian businessman and philanthropist Isaac Assa, is expanding to the United States, Costa Rica, Chile, Guatemala and other countries in Central America.

“Over the last year we directly developed unique connections between the State of Israel and Latin American countries,” said Assa on June 9 at ILAN’s first award ceremony, held in partnership with the Peres Center for Peace and Innovation in Tel Aviv-Jaffa.

“Through ILAN, we formed strategic alliances with a number of branches throughout America, which will strengthen the economic, diplomatic and social resilience of the countries,” Assa said.

“In a few years, the Spanish-speaking population in the United States will increase to 100 million people, and therefore strengthening these connections is a supreme goal in the interest of the states and the peoples. With the help of the Israeli brain, the innovation and the local courage, we will be able to make groundbreaking international achievements.”

ILAN presented Shimon Peres Lifetime Awards to internationally prominent Israelis who have promoted relations between Israel and Latin America in the areas of health, quality of environment, economy and technology.

Among the recipients were the Technion’s Prof. Shulamit Levenberg, who developed the technology behind Aleph Farms cultivated steak; Dr Amir Kereshonvich, chief of pediatric neurosurgery at Schneider Children’s Medical Center, who with his wife, Hila, set up a volunteer-led initiative to perform complicated brain surgeries on children from the developing world; Henrique Cymerman, an Israeli journalist of Portuguese-Sephardi descent who serves as the Middle East correspondent for a several media outlets and is president of the Chamber of Commerce between Israel-Jordan and the Persian Gulf States; Tato Bigio, founding partner and CEO of UBQ Materials, which converts household waste into recyclable raw materials; and Ella Castelenus, a new immigrant from Mexico who founded Hola – Land, a platform that connects Latin America and Israel, and a partner in Cantera Capital, a fund for enterprises in Israel and Mexico.

The Technion-Israel Institute of Technology and Rambam Health Care Campus together with philanthropists Andi and Larry Wolfe, announced the establishment of the Wolfe Center for Translational Medicine and Engineering

The Technion is one of the few academic institutions in the world in which the Faculty of Medicine operates alongside engineering and scientific faculties. The university conducts extensive teaching and research activities in the fields of medicine as well as biomedical engineering, computing, design, and architecture.

The Rambam Health Care Campus is heavily active in the research and innovation fields through its partnerships with its Division of Research, technology transfer company Rambam MedTech, and the MindUp incubator in cooperation with IBM, Medtronic, and Pitango VC.

The Wolfe Center will elevate the partnership between Rambam and the Technion and will serve as a platform for comprehensive clinical applied research to advance human health technologies that address unmet clinical needs. Interdisciplinary teams will collaborate to solve human health issues, translate research insights into innovative therapeutic tools, and train the next generation of doctors and engineers.  

The Center will be located within the Rambam campus inside the Helmsley Health Discovery Tower and serves as the first joint project of its kind between Rambam, academia, and the biomedical high-tech industry. The Tower will also host centers of excellence, clinical institutes, innovation centers, and several start-up companies, alongside an exhibition and visitor center.

“Research and innovation are critical components in the success of the healthcare system in the 21st century. The tremendous contribution of the Wolfe family will enable us to increase our capabilities. Research is now a necessity for keeping Israeli doctors relevant in a competitive and constantly evolving field. The new center will allow us to convince doctors who are engaged in the difficult, demanding clinical field to continue to work in a large medical center, by providing opportunities for advanced research,” said MikI Halberthal, professor and general director of Rambam Health Care Campus.

“Human health is one of the greatest challenges facing humanity in the 21st century and coping with this challenge requires a combination of capabilities from different worlds of content, from the patient’s bed and the doctors around it, to scientists and engineers from a variety of disciplines,” said Technion President Professor Uri Sivan. “Today, the Technion is creating a revolution aimed at connecting all those disciplines to deal with major challenges in human health, and the Wolfe Center will express the combination of the capabilities of one of Israel’s leading hospitals with a world-renowned scientific-technological university.”

The Israel Institute of Technology (TECHNION) has announced the establishment of the country’s first Artificial Intelligence (AI) research institute for medical technology solutions.

The Technion’s Zimin Institute for AI Solutions in Healthcare, which was jointly launched and operated with the Russian charity Zimin Foundation on Sunday, will focus on multidisciplinary research and technological development in human health and medicine using big data and computational learning, according to a statement from Technion.

Zimin Institute for AI Solutions intends to improve human healthcare on all levels, including hospitals, clinics, drug development, home therapy, and medical wearables. “This new centre is a crucial component of Technion President Uri Sivan’s goal of collaboration and connectivity between research, engineering, and medicine,” said Technion President Uri Sivan.

“It will support applied research that will speed the creation of new and important technologies with real-world applications,” he added.

The Israeli Institute of Technology continues to be at the forefront of groundbreaking solutions to help protect our planet.

This development coincides with Better Speech and Hearing Month

Israeli scientists at the Technion – Israel Institute of Science have engineered a working ear, alongside Sheba Medical Centre.

Led by Professor Shulamit Levenberg of the Faculty of Biomedical Engineering, the team combined techniques of organ printing, tissue engineering and the extraction of human cells to create a custom implant that can be used to replace ears that don’t develop properly in utero.

The scaffold, which allows for the formation of the new ear, is designed from a CT scan of the patient’s ear.

It is hoped the breakthrough will significantly help children with microtia – a condition in which the underdeveloped ear is small, malformed and sometimes unable to hear. 

Previously, it was treated using cartilage tissue from the ribs, which is both painful and comes with the risk of added complications. The new surgery can also be performed at the age of six instead of after 10, which may also help reduce the psychological effects for children who, up until now, have had to start school with a malformed ear.

It could also be tailored to “other applications, such as nasal reconstruction and fabrication of various orthopedic implants”, Professor Levenberg hopes.

Microtia affects 0.1% to 0.3% of births.

Each May, Better Hearing and Speech Month helps raise awareness about communication disorders and hearing health.

The Israeli Institute of Technology continues to be at the forefront of groundbreaking solutions to help protect our planet 

The Technion – Israel Institute of Technology signed a historic agreement with Morocco’s Mohammed VI Polytechnic University (UM6P) this week to promote academic cooperation between the two universities.

This document was said to be the first of its kind to be signed between these two institutions.

An agreement to recognize the academic collaboration was signed by UM6P President Mr. Hicham El Habti, Technion President Professor Uri Sivan, Senior Vice President of the Technion Professor Oded Rabinovitch, and Vice President of Research Professor Koby Rubinstein at a ceremony held at the Technion. The ceremony was chaired by Technion Vice President for External Relations and Resource Development Professor Alon Wolf.

The agreements were reached through the initiation of diplomatic relations between Israel and Morocco in December 2020 with the Abraham Accords. 

Technion President Professor. Uri Sivan addressed the delegation and said that their visit to the Technion “reflects a rapid and dramatic historical change in the region. We at the Technion are determined to participate in leading this process and building bridges through education and research. Since the Abraham Accords, we have received delegations from the UAE and Bahrain, countries that none of us ever imagined would come to visit. Both of our institutions – the Technion and UM6P – educate young people and equip them for the future. The cooperation we are establishing here today goes beyond its academic value; it is our duty to the region and to the future of the next generation.”

“Today we are signing a piece of paper,” The President of Morocco’s Mohammed VI University, Mr. Hicham El Habti, said at the ceremony, “but what is more important is what is behind it – the mutual desire for cooperation, which will lead to student and faculty exchange from both institutions. It is an honor to be here at the Technion – and a great responsibility. We are part of a historic era, and we must continue to strengthen ties between Morocco and Israel. As a very young university, we are open to international cooperation and are delighted to establish this relationship with you.”

After the signing, both presidents exchanged gifts. Mr. Hicham El Habti gave the Technion President a book on the history of Moroccan Jewry, and Prof. Sivan gave the UM6P President a glass engraving bearing the symbol of the Technion.

In March, the Technion received a historic visit from a Moroccan delegation led by El Habti.

“There are many similarities between Morocco and Israel,” said Prof. Koby Rubinstein, Executive Vice President for Research of the Technion, “both in the physical terrain and climatic conditions, as well as in our people and interests. This cooperation is important to us and has every reason to be successful.”

“We introduce a novel, customizable three-dimensional interface for producing scalable structures, utilizing real data collected from coral ecosystems,” explains Ph.D. student Natalie Levy.

(April 29, 2022 / JNS) The world’s coral reefs are becoming extinct due to many factors such as global warming and accelerated urbanization in coastal areas, which places tremendous stress on marine life.

“The rapid decline of coral reefs has increased the need for exploring interdisciplinary methods for reef restoration,” explains Natalie Levy, a Ph.D. student at Bar-Ilan University in Ramat Gan, Israel. “Examining how to conserve the biodiversity of coral reefs is a key issue, but there is also an urgent need to invest in technology that can improve the coral ecosystem and our understanding of the reef environment.”

In a paper published in the journal Science of the Total Environment, researchers from four of Israel’s leading universities highlight a three-dimensional printing method they developed to preserve coral reefs. Their innovation is based on the natural structure of coral reefs off the southern coastal Israeli city of Eilat, but their model is adaptable to other marine environments and may help curb reef devastation plaguing coral ecosystems around the world.

The joint research was led by Professor Oren Levy and Ph.D. student Levy of the Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University; Professor Ezri Tarazi and Ph.D. student Ofer Berman from the Architecture and Town Planning Faculty at the Technion–Israel Institute of Technology; Professor Tali Treibitz and Ph.D. student Matan Yuval from the University of Haifa; and Professor Yossi Loya of Tel Aviv University.

The process begins by scanning underwater photographs of coral reefs. From this visual information, a 3D model of the reef is assembled with maximum accuracy. Thousands of images are photographed and sent to the laboratory to calculate the complex form of the reef and how that form encourages the evolution of reef species diversity.

Next, researchers use a molecular method of collecting environmental genetic information, which provides accurate data on the reef’s organisms. This data is incorporated with other parameters and is fed into a 3D-technology algorithm, making it possible to build a parametric interactive model of the reef. The model can be designed to precisely fit the designated reef environment.

The final stage is the translation and production of a ceramic reef in 3D printing.

The reefs are made of ceramic that is naturally porous underwater, providing the most ideal construction and restoration needs to the affected area or for the establishment of a new reef structure as a foundation for the continuation of life. “Three-dimensional printing with natural material facilitates the production of highly complex and diverse units that is not possible with the usual means of mold production,” says Tarazi.

The process combines 3D-scanning algorithms, together with environmental DNA sampling, and a 3D-printing algorithm that allows in-depth and accurate examination of the data from each reef, as well as tailoring the printed model to a specific reef environment. In addition, data can be refed into the algorithm to check the level of effectiveness and efficiency of the design after it has been implemented, based on information collected in the process.

The workflow of 3D interface, starting with data collection using molecular tools and 3D imaging. Credit: Natalie Levy and Professor Ofer Berman of the Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University.

“Existing artificial reefs have difficulty replicating the complexity of coral habitats and hosting reef species that mirror natural environments. We introduce a novel, customizable 3D interface for producing scalable structures, utilizing real data collected from coral ecosystems,” explains Levy.

Berman adds that “the use of 3D printing allows for the extensive freedom of action in algorithm-based solutions, as well as the assimilation of sustainable production for the development of large-scale marine rehabilitation.”

This study meets two critical needs to save coral reefs, according to the researchers. The first is the need for innovative solutions that facilitate large-scale restoration that can be adapted to support coral reefs worldwide. The second is the recreation of a natural complexity of the coral reef, both in size and design, that will attract reef species such as fish and invertebrates that support the regrowth of natural coral reefs.

The researchers are currently installing several 3D-printed reefs in the Gulf of Eilat. They believe that the results they obtain will help them apply this innovation to other reef ecosystems around the world.

A new Technion study looks at how marine organisms produce hard tissues from the materials available to them, and under harsh and hostile conditions.

An international research group led by the Technion – Israel Institute of Technology has recently deciphered the process through which marine organisms develop their hard and durable skeletons.

The wonders of underwater engineering

The study, led by Prof. Boaz Pokroy, doctoral student Nuphar Bianco-Stein and researcher Dr. Alex Kartsman from the Technion Faculty of Materials Science and Engineering conducted the study with the assistance of Dr. Catherine Dejoie from the European Synchrotron Radiation Facility (ESRF) in Grenoble, France. The results were published in the Proceedings of the National Academy of Sciences in the US.

The researchers focused their efforts on the involvement of magnesium-containing calcite in the biomineralization process – the process by which living organisms produce minerals to harden or stiffen existing tissues. Calcite is a common mineral that constitutes about 4% of the mass of the Earth’s crust.

“Biomineralization processes build structures that surpass artificial products of engineering processes in many aspects, such as strength and resistance to fractures,” Pokroy said.

What can we learn from the starfish?

The researchers found that the deposits of calcite particles in magnesium-poor substances create compression in the organisms’ skeletons that increase their rigidity. This occurs naturally, without the need for mechanical compression used in the production of similar materials in classical synthetic engineering processes.

“We have discovered that this phenomenon occurs in a huge variety of creatures, even creatures from different kingdoms in the animal world, and we estimate that it is even broader than what we have discovered,” Pokroy said. “Therefore, it is likely to be a very general phenomenon.”

The study was supported by an EU grant from the European Research Council.

Nine different organisms were examined, including brittle stars, red algae, starfish, coral and sea urchins. In brittle stars, the crystallization process is used for its calcite lenses, which essentially function as eyes scattered all over their arms.

Red algae, however, use the magnesium-calcite crystals to coat all their cells and increase durability as the algae are subjected to the pressures and physical trauma of shallow waters.

“There is no doubt,” Pokroy concluded, “that we have a lot to learn from these biological processes, and that our findings may lead to improved engineering processes in a variety of areas.”

Israeli smart mobility company Innoviz Technologies, announced on MondGrowth of muscle tissue on a plant-based ‘scaffold’ marks another milestone in the development of cultivated meat using 3D bioprinting.

A bioprinted plant-based “scaffolding” helps the successful cultivation of edible muscle fibers, researchers from the Technion-Israel Institute of Technology have discovered.

The development of cultivated meat, i.e. meat that does not involve the raising and slaughtering of animals, is a potential solution for the growing need for meat products following population growth, the environmental damage caused by breeding cattle, and the increasing awareness to animal welfare.

To fulfill the promise of cultivated meat to meet various consumer expectations, there is a need for technologies that allow for the production of whole muscle cuts that are as similar as possible – in terms of taste, smell, and culture – to those slaughtered from animals.

The process is outlined in a new article in Biomaterials by Professor Shulamit Levenberg and Ph.D. student Iris Ianovici of the Faculty of Biomedical Engineering, in collaboration with cultivated meat producers Aleph Farms.

PhD student Iris Ianovici, left, and Professor Shulamit Levenberg of the Technion’s Faculty of Biomedical Engineering

Other partners in the research described in the article are Dr. Yedidya Zagury, Dr. Idan Redensky, and Dr. Neta Lavon.

Researchers think that besides the scientific-engineering accomplishment, this technology is likely to enable the robust production of cultivated meat at large scale in the near future.

Levenberg became involved in cultivated meat several years ago after recognizing that her inventions in tissue engineering for medical needs were relevant for growing cultivated meat. Her research on the subject led to the founding of Aleph Farms, which sponsored the research study now being published. Last year, Aleph Farms presented the first cultivated ribeye steak in history – created in the Levenberg lab – and has since pursued the development of new products. Aleph Farms’ CEO is Didier Toubia, Levenberg is Chief Scientific Advisor, and Lavon is the company’s CTO.

The ability to produce a wide variety of cultivated meat products was the primary focus of the present research, which sought to develop the technology for creating thicker cultivated steaks while using alternative materials as “scaffolding.”

Enabling the perfusion of nutrients across the thicker tissue has been a significant challenge, with most of the currently used scaffolding materials for growing tissues being derived from animals. In the article, the Technion researchers present a solution in the form of an alternative bio-ink, which is used to bioprint scaffolds from animal-free proteins, as well as living animal cells.

The bio-ink contains the cells that will form the muscle tissue – satellite cells originating from a biopsy taken from livestock, and is formulated by combining alginate (a compound found within the cell walls of brown algae) and proteins isolated from plants – soy or pea proteins. The printing process enables the creation of protein-enriched scaffolds with different geometries. The printing process is based on a method in which the bio-ink is deposited into a suspension bath that supports the materials during printing.

After the scaffolds were printed with the living animal cells, high cell viability was observed. Furthermore, the cells successfully matured to create muscle fibers as the tissue grew. Since the geometry of the scaffold can be controlled, it is possible to control the introduction of nutrients and the removal of waste from the developing tissue.

“In the engineering process we developed in the lab, we tried to mimic the natural process of tissue formation inside the animal’s body as much as possible,” Levenberg said.

“The cells successfully adhered to the plant-based scaffold, and the growth and differentiation of the cells proved successful as well. Our bio-ink led to a consistent distribution of the cells across the bioprinted scaffold, promoting growth of the cells on top of it. Since we used non-animal-derived materials, like pea protein, which is non-allergenic, our findings promise greater development of the cultivated meat market moving forward,” she added.

PixCell Medical’s HemoScreen performs a CBC in five minutes, enabling infection-vulnerable patients to spend less time in the clinic environment.

Chemotherapy patients are at major risk of infection because they are immunocompromised. Limiting the time they spend in hospitals or clinics for treatments could therefore be a lifesaver.

Israeli company PixCell Medical can help by enabling cancer patients to perform pretreatment blood tests rapidly onsite — or, in the future, at home.

PixCell’s HemoScreen device is FDA-cleared for point-of-care complete blood count (CBC) tests.

Using a disposable cartridge that includes all necessary reagents and requires no maintenance or calibration, HemoScreen delivers lab-accurate data from a single finger-prick of blood within five minutes.

CBC results show up on the HemoScreen in about five minutes. Photo courtesy of PixCell

“Even before we get approval for home use, we can improve the life of cancer patients dramatically,” says Armin Schon, PixCell’s chief commercial officer.

“They get blood drawn before chemotherapy and if their white blood cell count has recovered sufficiently since the last treatment, they can get the next dose. If not, they are sent home. They have to sit and wait till the central lab returns results, which takes half an hour to several hours,” he explains.

“This is very unpleasant for the patient and inefficient for the clinic’s workflow. Our CBC analyzer can shorten that wait time to a few minutes. A staff member can roll it around from patient to patient and within five minutes say, ‘You are good to go’ or ‘Sorry, come back next week.’”

Armin Schon, CCO of PixCell Medical. Photo courtesy of PixCell

A clinical trial in Denmark led by Changing Cancer Care successfully trained 12 breast-cancer patients to use PixCell’s HemoScreen to perform their CBC test at home. Their results were compatible to standard hospital lab results.

“With HemoScreen, we can potentially save patients significant time and energy exertion when undergoing these serious treatments, and also save time and costs for hospitals,” said Dr. Niels Henrik Holländer, head of Changing Cancer Care and an oncologist at Zealand University Hospital in Næstved.

Into the community

“From day one, the HemoScreen was developed with the goal to be usable by basically everyone with just half an hour or so of training,” says Schon.

“For maximum deployment we want to be independent of expert users, laboratory technicians and other highly skilled people who usually operate this type of equipment, and really go into the community,” he says.

“However, regulatory authorities are very hesitant to allow non-medical personnel to operate this type of equipment, so we have an uphill battle to convince them that this is a safe use and will bring value in the treatment of home-based patients. There’s only one way to do that, and that’s clinical trials.”

To that end, the Danish Ministry of Health has approved a second bigger trial to be done in Denmark and Germany that will include patients with various types of cancer at more advanced stages.

It is these patients who stand to benefit most from spending less time in a clinic, Schon points out.

“We believe that will provide the evidence we need to get approval in Europe for home-based CBC measurements,” he says, and FDA approval for home use could take several more years.

Meanwhile, PixCell won a grant from the International Health-Tech Pilot Program — an alliance between the Israel Innovation Authority and leading US and Europe hospitals — to develop and validate additional applications for HemoScreen.

In addition, the product was named a gold winner in the Testing and Diagnostic Products and Systems category in the 2022 Medical Design Excellence Awards and received Best-in-Show honors.

Devices in 18 countries

Headed by microfluidics expert Avishay Bransky, PixCell Medical was founded in 2009 and launched HemoScreen in the market two years ago.

Although the pandemic prevented the company from traveling internationally to demonstrate HemoScreen, several hundred devices were sold through distributors in 18 countries.

Now, says Schon, “production is fully loaded with orders. We have just opened a US subsidiary, so commercialization is going at full speed.”

Many hospitals have ordered HemoScreen to improve workflow, Schon reports. “Emergency departments in particular benefit from getting results in five minutes.”

However, the device originally was designed for “extreme point of care” uses, such as rural clinics.

It was for just such a purpose that PixCell donated a HemoScreen device, along with hundreds of cartridges, to Ukraine via the Ukrainian Embassy in Tel Aviv.

Schon says the HemoScreen could be used for quick testing and triaging of refugees on the border or in hospitals.

“The reason we dare to donate this system to Ukraine is that a nurse can unbox it and start testing – you just need electricity and reasonable temperatures. The box comes with a leaflet explaining how to do it, and there are short training videos. Within 15 minutes of unboxing you can be using the device.”

Another use of the HemoScreen is for assessing the effects of certain psychiatric drugs that require regular lab visits and venous blood draws because they have potentially lethal effects on the immune system that must be monitored, Schon explains. “We can revolutionize this area by reducing the inconvenience and taking the needle anxiety away.”